Phathom Pharmaceuticals (PHAT) PT Raised to $65 at Guggenheim
Guggenheim analyst Yatin Suneja raised the price target on Phathom Pharmaceuticals (NASDAQ: PHAT) to $65.00 (from $60.00) while maintaining a Buy rating.
You May Also Be Interested In
- UPDATE: RBC Capital Upgrades GMS Inc. (GMS) to Outperform
- HSBC Downgrades Halkbank (HAKAKAR:TI) to Reduce
- Daikin Industries Ltd. (6367:JP) (DKILY) PT Lowered to JPY17,000 at Morgan Stanley
Create E-mail Alert Related CategoriesAnalyst PT Change
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!